From clinical research to clinical practice: A 4-year review of ziprasidone

CNS Spectrums

Volumn 10, Issue 11, 2005, Pages 1-19

  Nemeroff, Charles B ^d   Lieberman, Jeffrey A ^e   Weiden, Peter J ^h   Harvey, Philip D ^c   Newcomer, John W ^f   Schatzberg, Alan F ^g   Kilts, Clinton D ^d   Daniel, David G ^a,b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b Department of Global Learning LLC ^*  (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Columbia University ^*  (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; KETOCONAZOLE; LITHIUM; MONOAMINE; NEUROLEPTIC AGENT; NORADRENALIN TRANSPORTER; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; ZIPRASIDONE;

AREA UNDER THE CURVE; BIPOLAR MANIA; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HUMAN; MANIA; META ANALYSIS; MOOD DISORDER; OBESITY; PRIORITY JOURNAL; QT PROLONGATION; RELAPSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TORSADE DES POINTES; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CONTROLLED CLINICAL TRIALS; DOPAMINE ANTAGONISTS; HUMANS; MOOD DISORDERS; PIPERAZINES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; THIAZOLES; TREATMENT OUTCOME;

EID: 28944452691     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl). 2001;155:128-134.
2. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001;62:12-18.
3. Brook S, Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl). 2005;178:514-523.
4. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
5. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychophamacol. 2003;28:1400-1411.
6. Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacol. 2004;177:207-216.
7. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel anti-psychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197-201.
8. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26;649-666.
9. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19):6-12.
10. 1-bistamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol. 2003;28:519-526.
11. Duman RS. Depression: a case of neuronal life and death? Biol Psychiatry. 2004;56:140-145.
12. Thome J, Foley P, Riederer P. Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses. Review article. J Neural Transm. 1998;105:85-100.
13. Arango C, Kirkpatrick B, Koenig J. At issue: stress, hippocampal neuronal turnover, and neuropsychiatric disorders. Schizophr Bull. 2001;27:477-480.
14. Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry. 2005;58:62-66.
15. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000;49(suppl 1):35S-42S.
16. Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol. 2003;23:229-232.
17. Miceli JJ, Wilner KD, Hansen RA. Single and multiple dose pharmacokinetics of ziprasidone under non-fasting conditions in healthymale volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):5S-13S.
18. Hamelin BA, Allard S, Laplante L, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy. 1998;18:9-15.
19. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics: a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):S71-S76.
20. Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol. 2000;49:(suppl 1):S65-S70.
21. Apseloff G, Muller D, Wilner KD, et al. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. Br J Clin Pharmacol. 2000;49(suppl 1):S61-S64.
22. Obach RS, Huynh P, Allen MC, Beedham C. Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol. 2004;44:7-19.
23. Geodon (package insert). New York, NY: Pfizer, Inc.; December 2003.
24. Murray S, Mandel FS, Loebel A. Optimal initial dosing of ziprasidone: clinical trial data. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
25. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818-825.
26. Weiden PJ, Iqbal N, Mendelowitz AJ, Tandon R, Zimbroff DL, Ross R. Best clinical practice with ziprasidone: Update after one year of experience. J Psych Pract. 2002;8:81-97.
27. Joyce AT, Harrison DJ, Ollendorf DA. Effect of ziprasidone initial dosing on discontinuation. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
28. Pozzi L, Acconcia S, Ceglia I, et al. Stimulation of 5-hydroxytryptamine (5-HT(2C)) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J Neurochem. 2002;82:93-100.
29. Bonaccorso S, Meltzer HY, Li Z, et al. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacol. 2002;27:430-441.
30. Harrïgan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62-69.
31. Daniel DG. Tolerability of ziprasidone: an expanding perspective. J Clin Psychiatry. 2003;64(suppl 19):40-49.
32. Deutschman DA, Deutschman DH. High-dose ziprasidone: Efficacy and tolerability in clinical practice. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
33. Miceli JJ, Murray S, Sallee FR, Tensfeldt TG, Versavel M. Phamacokinetic and pharmacodynamic QTc profile of oral ziprasidone in pediatric and adult subjects following single-dose administration. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
34. Lindenmayer JP, Czobor P, Volavka J, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry. 2004;65:551-556.
35. Lindenmayer JP, Bernstein-Hyman R, Grochowski S, Bark N. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology. 1995;28:22-31.
36. Potkin SG, Anand R, Alphs L, Fleming K. Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide. Schizophr Res. 2003;59:59-66.
37. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004;68:1-9.
38. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296-304.
39. Addington D, Pantelis C, Dineen M. Ziprasidone vs risperidone in schizophrenia: 52 weeks comparative data. Poster presented at: the 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
40. Simpson GM, Glick ID, Weiden PJ, Romnno SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837-1847.
41. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J. 2000;321:1371-1376.
42. Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Tech Assess. 2003;7(13):1-193.
43. Lieberman JA, Stroup, TS, McEvoy JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
44. Harrison DJ, Joyce AT, Olldendorf DA. Impact of atypical agents on outcomes of care in schizophrenia. Poster presented at: 158th Annual Meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, GA.
45. Siris SG. Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatry. 2000;157:1379-1389.
46. Keck PE Jr, Reeves KR, Harrigan EP, et al. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol. 2001;21:27-35.
47. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacol. 1999;20:491-505.
48. Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl). 1998;140:173-184.
49. Kane JM. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. J Clin Psychiatry. 2003;64(suppl 19):19-25.
50. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14:1-21.
51. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301-307.
52. Davalos DB, Compagnon N, Heinlein S, Ross RG. Neuropsychological deficits in children associated with increased familial risk for schizophrenia. Schizophr Res. 2004;67:123-130.
53. Palmer BW, Heaton RK, Paulsen JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology. 1997;11:437-446.
54. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176-184.
55. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426-445.
56. Harvey PD, Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;60:101-113.
57. Harvey FD, Siu CO, Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacol. 2004;172:324-332.
58. Harvey PD, Bowie CR, Loebel A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a 6-month, randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsych Clin Neurosci. In press.
59. Hegarty JD, Baldessarini RJ, Tohen M. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409-1416.
60. Dickerson FB, Ringel, N, Parents F. Predictors of residential independence among outpatients with schizophrenia. Psychiatr Serv. 1999;5:515-519.
61. Macdonald EM, Hayes RL, Baglioni AJ Jr. The quantity and quality of the social networks of young people with early psychosis compared with closely matched controls. Schizophr Res. 2000;46:25-30.
62. Haukka J, Suvisaari J, Lonnqvist J. Fertility of patients with schizophrenia, their siblings, and the general population: a cohort study from 1950 to 1959 in Finland. Am J Psychiatry. 2003;160:460-463.
63. Purnine DM, Carey KB, Maistro SM, Karey MP. Assessing positive and negative symptoms in patients with schizophrenia and mood disorders. J Nerv Ment Dis. 2000;188:653-661.
64. Loebel A, Siu C, Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr. 2004;9:357-364.
65. The World Health Report: 2001. Mental Health: New Understanding, New Hope. Available at: http://www.who.int/whr/2001/en/. Accessed October 4, 2005
66. Atato M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17:207-215.
67. Schooler NR. Maintaining symptom control: review of ziprasidone long-term efficacy data. J Clin Psychiatry. 2003;64(suppl 19):26-32.
68. Simpson GM, Weiden PJ, Loebel A, Warrington L, Yang R. Ziprasidone: long-term post-switch efficacy in schizophrenia. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
69. O'Connor R, Schooler NR. Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]. Schizophr Res. 2003;60:319-320.
70. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64:580-588.
71. Weiden PJ, Daniel DG, Simpson GM, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:1-6.
72. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997;23:663-674.
73. Basu A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res. 2004;71:445-462.
74. Essock SM, Hargreaves WA, Covell NH. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharm Bull. l996;32:683-697.
75. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med. 1997;337:809-815.
76. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res. 2002;50:1-10.
77. Moncrieff J. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br J Psychiatry. 2003;183:161-166.
78. Kane J, Khanna S, Giller E, Rajadhyaksha S, Loebel A, Siu C. Efficacy and tolerability of ziprasidone in treatment-resistant schizophrenia. Int Clin Psychopharmacol. In press.
79. Rothschild AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am. 1996;19:237-252.
80. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
81. Rush AJ, Thase ME, Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53:743-753.
82. Kohler CG, Lallart EA. Postpsychotic depression in schizophrenia patients. Curr Psychiatry Rep. 2002;4:273-278.
83. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60:1218-1226.
84. Tohen M, Zhang F, Keck PE, et al. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. J Affect Disord. 2001;67:133-140.
85. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2000;57:841-849.
86. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:62-69.
87. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41:1216-1223.
88. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003;28:182-192.
89. Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacol. 2003;166:315-332.
90. Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057-1065.
91. Potkin SG, Keck P, Giller E, Ice K, Warrington L, Mandel FS. Ziprasidone in bipolar mania: efficacy across patient subgroups. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
92. Keck PE, Potkin S, Warrington L, Loebel A, Giller E, Batzar E. Efficacy and safety of ziprasidone in bipolar disorder: short- and long-term data. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
93. Papakostas GI, Petersen TJ, Neirenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) fot SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65:217-221.
94. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality. Br J Psychiatry. 2001;179:498-502.
95. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11-53.
96. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-850.
97. Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000;61(suppl 9):47-51.
98. Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001;35:196-202.
99. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):4-18.
100. Zhang ZJ, Yao KJ, Liu W, et al. Effects of antipsychotics on far deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:58-02.
101. Newcomer J. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
102. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
103. Simpson GM, Click ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837-1847.
104. Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005;162:1535-1538.
105. Sorensen SV, Leaderer MC, Harrison DJ, et al. Psychiatric and metabolic outcomes of antipsychotics in schizophrenia. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2005; New York, NY
106. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123-130.
107. Cheer SM, Wagstaff AJ. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs. 2004;18(3):173-199.
108. Fitzsimons J, Betk M, Lambert T, Bourin M, Dodd S. A review of clozapine safety. Expert Opin Drug Saf. 2005;4(4):731-744.
109. Pajonk FG. Risperidone in acute and long-term therapy of schizophrenia-a clinical profile. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):15-23.
110. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-161.
111. Moller HJ. Risperidone: a review. Expert Opin Pharmacother. 2005;6(5):803-818.
112. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-1736.
113. Clozaril (package insert). East Hanover, NJ: Novartis; January 2003.
114. Zyprexa (package insert). Indianapolis, IN: Eli Lilly; March 2004.
115. Abilify (package insert). Otsuka Pharmaceutical Co, Ltd (Tokyo) and Bristol-Myers Squibb (Princeton, NJ); March 2004.
116. Risperdal (package insert). Titusville, NJ: Janssen Pharmaceutica; December 2003.
117. Setoquel (package insert). Wilmington, DE: AstraZeneca; January 2004.
118. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs. 2003;17:423-430.
119. Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. Arch Int Med. 2004;164:943-948.
120. Goldberg RJ, Bengtson J, Chen ZY, Anderson KM, Locati E, Levy D. Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience). Am J Cardiol. 1991;67:55-58.
121. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):4-18.
122. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
123. Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997;58:13-17.
124. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425-433.
125. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
126. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
127. Harrison DJ, Leaderer MC, Loebel A, Murray S. Ziprasidone vs. olanzapine: change in CHD risk during a 6 week trial. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; Atlanta, GA.
128. Newcomer J, Lebovitz H. Course of weight and metabolic benefits one-year after switching to ziprasidone. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; Atlanta, GA.
129. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968-976.
130. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:115-126.
131. Woolforton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167:1269-1270.
132. FDA Warning about Hyperglycemia and Atypical Antipsychotic Drugs, June 2004. Available at; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/ printer. cfm?id=229. Accessed October 4, 2005.
133. Weiden PJ, Mackell J, Macdonell D. Obesity as a risk factor for noncompliance. Schizophrenia Res. 2004;66:51-57.